HDAX Therapeutics is developing best-in-class HDAC6-targeting small-molecule therapeutics via a novel molecular recognition mechanism aimed at overcoming weak binding, poor pharmacokinetics, and off-target toxicities. The company’s platform originates from over seven years of research in Professor Patrick Gunning’s lab at the University of Toronto. HDAX is focused on discovery and preclinical development toward candidate nomination across neurological and cardiometabolic indications. Management emphasizes the potential for differentiated safety and efficacy versus prior HDAC6 efforts. The company is privately held and plans to use proceeds from its seed financing to advance its pipeline programs and nominate a preclinical development candidate. HDAX highlights a leadership team with deep small-molecule development expertise.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2024